Last reviewed · How we verify
LAYLA tablet
LAYLA tablet is a selective serotonin reuptake inhibitor (SSRI) that works by increasing the levels of serotonin in the brain.
LAYLA tablet is a selective serotonin reuptake inhibitor (SSRI) that works by increasing the levels of serotonin in the brain. Used for Major depressive disorder, Generalized anxiety disorder.
At a glance
| Generic name | LAYLA tablet |
|---|---|
| Also known as | LAYLA 405.4mg |
| Sponsor | PMG Pharm Co., Ltd |
| Drug class | SSRI |
| Target | Serotonin transporter |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
This increase in serotonin levels helps to improve mood, reduce anxiety, and prevent the recurrence of depression. SSRIs like LAYLA tablet are commonly used to treat major depressive disorder, generalized anxiety disorder, and other conditions. They can take several weeks to start working and may have side effects such as nausea, dizziness, and insomnia.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
Common side effects
- Nausea
- Dizziness
- Insomnia
Key clinical trials
- To Compare the Efficacy and Safety of LAYLA in Osteoarthritis Patients of the Knee (PHASE4)
- To Compare the Efficacy and Safety of LAYLA in Osteoarthritis Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LAYLA tablet CI brief — competitive landscape report
- LAYLA tablet updates RSS · CI watch RSS
- PMG Pharm Co., Ltd portfolio CI